SCHEMBL7514744

SCHEMBL7514744

O=C1Nc2ccccc2C1c1ccc(O)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.41
IDO1 P14902 4/20 0.41
TDO2 P48775 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
JAK2 O60674 1/20 0.38
GSK3B P49841 1/20 0.38
KDM4E B2RXH2 4/20 0.37
MAPT P10636 3/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CACNB4 O00305 1/20 0.37
CACNA1A O00555 1/20 0.37
CACNA1G O43497 1/20 0.37
CACNG3 O60359 1/20 0.37
CACNA1F O60840 1/20 0.37
CACNA1H O95180 1/20 0.37
CACNB3 P54284 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7852811 0.82 IDO1 (0.49) IDO1TDO2GSK3BKDM4EMAPT
SCHEMBL5858697 0.77 CACNB4 (0.47) IDO1TDO2MAPTCACNB4CACNA1A
SCHEMBL3078111 0.76 JAK2 (0.53) IDO1TDO2JAK2GSK3BKDM4E
SCHEMBL30564910 0.76 JAK2 (0.53) IDO1TDO2JAK2GSK3BKDM4E
SCHEMBL16634786 0.73 MAPT (0.49) IDO1TDO2MAPTCACNB4CACNA1A
SCHEMBL5435436 0.73 MAPT (0.56) IDO1MAPTCACNB4CACNA1ACACNA1G
SCHEMBL4589633 0.72 TSHR (0.41) IDO1KDM4EMAPTCACNB4CACNA1A
SCHEMBL7471103 0.71 MAPT (0.41) IDO1CA1CA2KDM4EMAPT
SCHEMBL5678203 0.71 MAPT (0.44) IDO1CA12CA1CA2CA9
SCHEMBL281695 0.71 RAB9A (0.48) IDO1TDO2MAPTRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020102608-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2002-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020102608-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease PTPRJ, ERBB2, JAK2 ESR1 1189/4885IDO1 95/4885TDO2 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.